Non-intoxicating
CBD is a non-psychoactive cannabinoid; it does not produce a “high”.
The record
Evidence & Legal Context
Evidence-based regulation protects patients, respects the law, and supports innovation. The scientific record, international obligations, and court decisions point to the same conclusion: proportionate regulation — not prohibition — is the right path.
Key facts
Safety profile
The WHO’s Expert Committee on Drug Dependence found CBD “generally well tolerated, with a good safety profile” (2018).
An authorised medicine
Purified CBD is an authorised medicine in the EU for certain seizure disorders, assessed by the European Medicines Agency.
Real-world evidence
Across Europe, patients — many of them seniors managing chronic conditions — report meaningful benefit. This real-world experience is an essential part of the totality of evidence, particularly on safety, tolerability and quality of life, and should not be dismissed because it does not come from randomised trials.
Calibrated to the approved evidence dossier — site claims may not go beyond it.
The precursor claim, examined
An evidentially limited hypothesis is not a proven danger.
The current restriction proposals rest on the claim that CBD is a “drug precursor”. The document advancing that framing — INCB PP Notice No. 1/2026 — itself records three things: that pure CBD is not controlled under the international drug control conventions; that the evidence for CBD’s use as a starting material is “limited”; and that the single documented criminal case (an HHC network in Romania, 2022–2023) used industrial hemp, not CBD. There is a fundamental difference between an evidentially limited hypothesis and a proven danger — and that difference is exactly what a transparent assessment would establish.
Downloadable resources
Each source is hosted locally with a one-line provenance description.